boston bio 2026: From AI Models to Auditable Decisions

A Look Ahead to Biotech Week Boston 2026: As AI Enters Biomanufacturing, Value Must Shift from Models to Auditable Decisions

 1. The focus of this boston bio event isn’t on how smart AI is, but whether it can be integrated into real-world development processes

 From September 22 to 25, 2026, Biotech Week Boston 2026 will take place at the Hynes Convention Center in Boston, USA. Organized by Informa Connect, this boston bio event covers the entire drug development value chain. The BioProcess International (BPI) conference, as its flagship component, will focus on topics such as cell line development, upstream and downstream processes, digital biomanufacturing, CMC strategies, cell and gene therapy, and CDMO collaborations.According to current information on the conference website, the event is expected to attract more than 5,000 attendees over the course of the week. It is important to note that the 2025 conference drew more than 4,000 attendees—a historical figure—while the 2026 figure of more than 5,000 is a forecast for that year; data from these two years should not be conflated.

 This conference is of particular interest to professionals in the pharmaceutical industry because it brings together discussions on drug discovery, clinical development, and biomanufacturing on a single platform.Over the past two years, discussions on the application of AI in biopharmaceuticals have largely focused on molecular generation and screening in the discovery phase; however, BPI’s agenda shifts the focus back to process development and the manufacturing floor. This agenda structure itself sends a clear signal: whether AI can truly create value depends on its ability to be integrated into controlled development processes—not merely on producing impressive metrics in academic papers.

 Table 1-1: Basic Information on Biotech Week Boston 2026

Program	Content	Source
Dates	September 22–25, 2026	BPI Official Website
Venue	Hynes Convention Center, Boston, USA	BPI Official Website
Organizer	Informa Connect	Conference Website
Flagship Section	BioProcess International (BPI)	Conference Website
Estimated Attendance for 2026	Over 5,000	Conference Website (2026 Projections)
Actual Attendance in 2025	Over 4,000	Conference Overview (2025 Historical Data)
Official Website	informaconnect.com/biotech-week-boston/	Conference Website

 The table above summarizes the event’s basic information. It is important to note the difference in the basis for the attendance figures: “more than 5,000” is the forecast from the 2026 event’s official website, while “more than 4,000” is historical data from 2025.When citing these two figures in formal writing, the year must be specified to prevent readers from mistaking the 2025 attendance figure for the actual 2026 attendance. This rigor in data methodology is precisely the writing-level manifestation of the central theme repeatedly emphasized in this article: “AI projects require verifiable evidence.”

 1.1 BPI Brings AI Back from the Realm of Speculation to Manufacturing Reality

 The agenda areas already listed on the BPI website include cell line development, upstream processes, downstream purification, digital biomanufacturing, CMC strategies, and cell and gene therapy. These areas cover the entire process chain for biopharmaceuticals, from cell line construction to the final product.BPI’s value lies in shifting the focus of AI discussions from “discovery narratives” back to “manufacturing realities.” In the discovery phase, an AI model may claim to have generated tens of thousands of candidate molecules; however, in the manufacturing phase, the criteria for evaluation become whether the model can reduce unexpected events during scale-up, enhance understanding of the process, and improve quality decisions.

 Specifically, the criteria for assessing AI’s value in the BPI context can be summarized in three points: First, does the model reduce unexpected events during the scale-up process from the laboratory to production—for example, by predicting metabolic drift or product aggregation trends during cell culture, enabling process teams to adjust parameters in advance? Second, does the model enhance understanding of the process—for example, by correlating Process Analytical Technology (PAT) data with product attributes to help teams understand which parameters truly impact product quality?Third, does the model improve quality decision-making, such as by assisting in determining batch acceptance during release testing or providing data-driven root cause analysis during nonconformance investigations? Any model that fails to meet even one of these three criteria is unlikely to be recognized as having production value within the BPI discussion framework.

 Table 1-2: BPI Core Agenda Directions and AI Value Assessment Criteria

BPI Agenda Directions	Potential AI Application Scenarios	Value Assessment Criteria	Current Maturity Level
Cell Line Development	Clone Screening Prediction and Stability Assessment	Can it shorten the cell line screening cycle and improve the accuracy of stability predictions?	Moderate
Upstream Process	Feeding Strategy Optimization, Growth Curve Prediction	Can metabolic abnormalities and yield fluctuations be reduced in actual production batches?	Moderate
Downstream Purification	Optimization of chromatography conditions, impurity prediction	Can it improve recovery rates and reduce the risk of impurity levels exceeding limits?	Low
Digital Biomanufacturing	Process monitoring, anomaly detection, digital twin	Can CPP be linked to CQA and operations adjusted within specified limits?	Early development stage
CMC Strategy	Quality Prediction, Stability Modeling	Can it support data package integrity in regulatory communications?	Low
Cell and Gene Therapy	Efficacy Prediction, Batch Consistency Assessment	Ability to provide reliable process understanding under small-sample conditions	Extremely low

 The table above lists the AI application scenarios and value assessment criteria for BPI’s six core areas. The “Current Maturity” column reveals the differences—AI applications in cell line development and upstream processes are relatively mature, as these two areas have accumulated a significant amount of structured data; conversely, AI applications in CGT and CMC strategy are less mature, due to limited data volumes or incomplete integration with quality management systems.This disparity in maturity means that attendees need to approach different agenda items with different questions: for mature areas, focus on implementation case studies and quantifiable benefits; for less mature areas, focus on the data foundation and validation pathways.

 1.2 A conference covering the entire value chain is better suited for assessing whether data can flow across stages

 The agenda for Biotech Week Boston covers the entire value chain from drug discovery through clinical trials to manufacturing, but this coverage does not imply that every segment is equally important. The best way to assess the value of a full-value-chain conference is to examine whether data can flow across stages—whether data from the discovery phase can support the selection of clinical candidates, whether signals generated in the clinical phase can be fed back into process and quality decisions, and whether data from the manufacturing phase can support the chain of evidence during regulatory review.

 In drug development practice, data silos between these three stages are a widespread problem. Candidate molecules selected by discovery teams often lack the manufacturability data required by process teams; safety signals observed by clinical teams may not be systematically fed back into the quality standards set by manufacturing teams; and batch data accumulated by manufacturing teams may be difficult to explain during regulatory communications due to a lack of upstream biological correlation.For AI to create true value along this value chain, it must be able to connect this cross-stage data—linking molecular structure to process developability, clinical adverse events to product attributes, and manufacturing parameters to regulatory-acceptable quality ranges.

 Table 1-3: Framework for Examining Data Flow in the Drug Development Value Chain

Data Flow Direction	Questions to Be Answered	Potential Role of AI	Current Obstacles
Discovery to Clinical	Do AI-screened candidate molecules have verifiable target evidence and data supporting their developability?	Linking molecular structure to biological hypotheses	Incomplete target validation data
Transition from Clinical to Process Quality	Can clinical safety signals be traced back to differences in product attributes?	Correlating clinical adverse events with CQA deviations	Clinical Data Not Integrated with Manufacturing Data
Transition from Manufacturing to Regulatory Affairs	Can Batch Data Support Quality Arguments During Regulatory Review?	Providing Data-Driven Quality Trend and Deviation Analysis	Inconsistent data formats and incomplete audit trails
Transition from Regulatory Compliance to Process Discovery	Can Regulatory Feedback Guide Future Molecular Design and Process Improvements?	Transforming Review Comments into Design Constraints	Lack of Systematic Feedback Mechanisms

 The data flow verification framework presented in the table above can serve as a reference for participants to evaluate AI tools.An AI system that truly delivers value should provide verifiable connections along at least one data flow direction—whether linking molecular structure data to developability scores, correlating clinical signals with product attribute deviations, or associating manufacturing parameters with quality trends. If an AI tool operates solely within a single phase and cannot transmit information across phase boundaries, its value is limited to point-specific optimization rather than systematic process improvement.

 Action Recommendation: When planning their BPI conference schedule, attendees should prioritize sessions based on data flow directions rather than agenda topics.Prioritize sessions that discuss cross-phase data connectivity, such as those titled “From Process Data to Quality Decisions” or “Clinical Signals Feeding Back into Manufacturing.” If a session only lists single-phase AI applications, attendees should ask the presenter how the tool interfaces with data from upstream and downstream phases. This line of questioning helps attendees quickly identify which AI projects have truly entered the development process and which remain at the proof-of-concept stage.

 During their pre-conference preparation, attendees should also complete a fundamental task: compile a list of AI tools currently in use or under evaluation within their organization, annotate the current status of each tool (exploration, pilot, deployment, controlled process), and list any unanswered validation questions.This list will serve as a reference framework during the BPI agenda—when hearing about a specific case study, attendees can immediately compare it with similar projects within their own organizations to identify gaps and areas for improvement. If attendees arrive at the conference with no prior knowledge, it will be difficult for them to make substantive judgments within the limited time available.

 Another pre-conference preparation step is to review the agenda outline and speaker biographies published on the BPI website. The agenda outline helps attendees anticipate which sessions may involve soft promotion by vendors and which are more likely to feature substantive technical discussions.Speaker backgrounds are also crucial: speakers from pharmaceutical companies’ manufacturing departments typically share practical case studies, while those from suppliers may focus on product promotion, and speakers from regulatory agencies may reveal policy trends. Adjusting expectations based on the speaker’s background can enhance the efficiency of conference participation.

 2. Success in AI-driven drug discovery can no longer be measured solely by the number of candidate molecules

 Industry analysis suggests that by 2026, the role of AI in the biopharmaceutical sector will undergo a fundamental shift—the industry will no longer blindly tout the concept of “AI-generated targets,” but will instead focus on whether AI-generated molecules have actually passed Phase II/III clinical validation. This assessment points to a core issue: the standard for success in AI-driven drug discovery is shifting from “the number of candidate molecules” to “clinical validation results.”In recent years, numerous AI-driven drug discovery companies have claimed to have generated a large number of candidate molecules, but questions such as whether these molecules have entered human trials, whether the trial designs are sound, and whether the models’ contributions can be distinguished from those of traditional R&D activities have often gone unanswered.

 From the perspective of industry investment and financing, capital’s attitude toward AI-driven drug discovery has also shifted from “beautiful science” to “clinical outcomes.” Investors are no longer satisfied with seeing algorithms achieve high scores in academic papers; they demand to see real-world data once candidate molecules enter clinical trials. This shift in attitude means that AI-driven drug discovery companies must demonstrate that their models can not only generate molecules at the computational level but also produce verifiable results at the clinical level.

 Table 2-1: Validation Dimensions for AI Drug Discovery Projects

Validation Dimensions	Questions to Be Addressed	Common Ways to Dodge the Issue	Data to Be Sought
Target Evidence	Has the AI-selected target undergone independent biological validation?	Vague statements such as “screened by AI”	Validation data for the target in an independent cohort
Contribution to Molecular Design	What is the specific contribution of AI to molecular design?	Combining AI-assisted and AI-designed approaches	Comparing the differences between AI-driven design and traditional design
Entry into Clinical Trials	Will the candidate molecules proceed to human trials?	Listing only preclinical data	Clinical Trial Registration Number and Enrollment Status
Control Design	Does the clinical trial have a valid control group?	Claim that a single-arm trial is sufficient	Control group configuration and primary endpoint
Effect Size	Did the clinical effect size meet the prespecified criteria?	Only statistical significance is reported	Effect size and clinical significance
Cost and Time	Has AI truly shortened R&D time or reduced costs?	Vague claims of efficiency improvements	Comparison with the Baseline of Traditional Projects

 The table above lists six dimensions to examine when evaluating AI-driven drug discovery projects. The core logic behind these six dimensions is that AI’s contribution to drug discovery must be decomposable, verifiable, and quantifiable.“Decomposable” means being able to clearly articulate AI’s specific role in molecular design—whether it generated entirely new structures, optimized existing lead compounds, or assisted in selecting decision paths; “verifiable” means that AI’s outputs can be confirmed through experimental or clinical data; “quantifiable” means being able to specify how much time or cost AI has saved compared to traditional methods.

 2.1 Model Outputs Must Be Linked to Verifiable Biological Hypotheses

 If a candidate molecule generated by an AI model cannot be traced back to a specific biological hypothesis, it is difficult to assess its probability of clinical success. The connection between model outputs and biological hypotheses is the dividing line between “AI-driven discovery” and “AI-generated randomness.” When evaluating AI-driven drug discovery projects, the following questions should be asked:What are the sources of the training data—public databases, internal company screening data, or literature mining? Does evidence for the target exist independently of the model—is there independent biological experimentation supporting the association between the target and the disease? What are the molecular selection criteria—are they based on a composite score of binding affinity, selectivity, or ADMET properties? Which failed candidates were included in the experimental validation—are models that list only successful cases statistically insignificant?

 These questions may seem basic, but in actual AI drug discovery marketing, many projects sidestep them. A common practice is to lump all computational tools under the umbrella term “AI R&D”—from simple QSAR models to deep generative models, and from molecular docking to free-energy perturbation—labeling any method that uses computation as “AI.” This approach not only obscures AI’s true contribution but also prevents regulators and investors from determining which technologies genuinely drive drug discovery.In future expansions of this article, the author should distinguish between three distinct categories of AI applications: AI discovery (models that directly generate new molecules), AI optimization (models that improve existing lead compounds), and AI-assisted decision-making (models that provide ranking or screening recommendations). These three categories require different levels of validation evidence.

 Action Recommendation: When attending presentations on AI-driven drug discovery, attendees should prepare a validation checklist—documenting the sources of model training data, the status of target-independent validation, molecular selection criteria, the number of failed candidates, and the scope of experimental validation. If presenters cannot answer these questions, their projects should be classified as “concept demonstrations” rather than “validated applications.” This classification helps attendees avoid mistaking unvalidated AI projects for mature applications when reviewing case studies after the conference.

 2.2 Phase II and Phase III Results Will Redefine the Value of AI Projects

 The number of AI-designed drugs entering clinical trials is increasing, but most remain in Phase I or early Phase II. The true test lies in Phases II and III, as results from these two phases will redefine the value of AI-driven drug discovery projects. When evaluating Phase II/III results, attention should be paid to the following dimensions: Are the patient selection criteria reasonable—does AI-assisted patient stratification result in a less representative enrolled population?Are the primary endpoints predefined—or have endpoints been adjusted based on interim data? Is the control group scientifically designed—has a head-to-head comparison been conducted against existing standard-of-care treatments? Is the effect size clinically meaningful—statistical significance does not equate to clinical significance. What are the causes of failure—is it incorrect target selection, defects in molecular properties, or issues with the clinical trial design? Are the results reproducible, and can consistent conclusions be drawn across different populations or centers?

 Even if clinical results are positive, it is necessary to determine exactly what time or costs AI has reduced; one cannot simply infer the algorithm’s effectiveness based on the results alone.For a clinically successful AI project, if it cannot demonstrate how much time AI saved during R&D, how many rounds of compound synthesis were reduced, or how much screening costs were lowered, then its “AI attributes” lack quantitative support. Conversely, for a clinically failed AI project, if the failure analysis can clarify which aspects the AI model predicted correctly and which it predicted incorrectly, it can actually provide substantively valuable information for subsequent model improvements.

 Table 2-2 Evaluation Framework for AI Drug Discovery Projects in the Clinical Phase

Evaluation Dimensions	Phase I Focus Areas	Phase II Focus Areas	Phase III Focus Areas
Patient Selection	Safety and Tolerability	Is AI stratification appropriate?	Is the sample sufficiently representative?
Primary Endpoint	Safety and PK	Strength of Efficacy Signals	Confirmatory Evidence of Efficacy
Study Design	Typically uncontrolled	Randomized controlled trial design	Head-to-head comparison of standard treatments
Effect Size	Preliminary safety margin	Assessment of clinical significance	Confirmatory effect size
Failure Analysis	Less	Need to distinguish between target- and molecule-related issues	Requires a comprehensive root cause analysis
Quantification of AI Contribution	Number of Compound Synthesis Iterations	Comparison of screening costs	Comparison of Total R&D Time

 The table above illustrates the evaluation priorities for AI-driven drug discovery projects at different clinical stages. Phase I primarily focuses on safety and pharmacokinetics; at this stage, AI’s contribution can be preliminarily assessed through the number of compound synthesis rounds and screening costs. Phase II requires attention to efficacy signals and clinical relevance; at this stage, a distinction should be made between issues related to target selection and those related to molecular properties. Phase III requires confirmatory evidence; at this stage, AI’s contribution should be quantified through a baseline comparison of total R&D time.If an AI project yields positive results in Phase III but its contribution cannot be quantified, it should be classified as “AI-assisted drug development” rather than “AI-driven drug discovery.”

Action Recommendation: Attendees should pay close attention to the agenda items in the BPI and Joint Sessions discussing clinical progress in AI-driven drug discovery, focusing on recording the clinical phase, number of enrollees, primary endpoints, and preliminary results. When organizing case studies after the conference, categorize them into three groups: “Already in Phase II/III with publicly available data,” “In Phase I but with no results yet,” and “Preclinical data only.” This categorization helps avoid overinterpreting early-stage projects as success stories.

 From an industry perspective, the validation pathway for AI-driven drug discovery is undergoing a recalibration. In the past, some companies claimed that AI had reduced early-stage discovery time from 4 to 5 years to 18 months or even less, but these claims largely lacked quantifiable baseline comparisons.A true baseline comparison must answer the following questions: How many rounds of compound synthesis, how many screening experiments, and how much time and cost would be required to screen an equivalent number of candidate molecules using traditional methods? What specific reductions have AI methods achieved across these dimensions? If these figures cannot be independently verified, claims of time savings lack substantive support.

 At the same time, the biological plausibility of target selection is another issue that is often sidestepped. An AI model can identify hundreds of potential targets from genomic data, but if these targets lack independent biological validation—such as gene-knockout phenotypes in animal models, clinical genetic evidence, or published studies on mechanisms of action—then the targets selected by the model represent merely statistical correlations rather than causal hypotheses.Distinguishing between statistical associations and causal hypotheses is a fundamental threshold for evaluating the scientific rigor of AI-driven drug discovery projects.

 Based on publicly available information, several AI-driven drug discovery companies currently have candidate molecules in clinical trials. Clinical data from these projects will be gradually disclosed over the next two to three years, at which point the industry will, for the first time, gain access to large-scale clinical validation results for AI-designed drugs.If attendees encounter relevant case studies during the BPI agenda, they should focus on recording the following information: the candidate molecule’s target and indication; the specific proportion of AI’s contribution to molecular design; the clinical phase and number of enrolled patients; the primary endpoint design; and preliminary signals regarding safety and efficacy. This information will be used when compiling case studies after the conference to assess the true progress of AI-driven drug discovery.

 One trend to watch out for is that some AI-driven drug discovery companies, following clinical failure, tend to attribute the failure to issues with target selection or clinical trial design rather than problems with the AI model itself. While this attribution may be partially valid, if the AI model cannot provide directions for improvement during failure analysis—such as identifying biases in molecular property predictions or inaccuracies in ADMET predictions—then there is a lack of evidence supporting the model’s “learning” capability.A truly capable AI system should be able to generate actionable recommendations for improvement following a failure, rather than merely claiming it will perform better next time.

 Table 2-3: Validation Checklist for AI-Driven Drug Discovery Companies

Checklist Item	Details	Data Source	Current Availability
Candidate Molecular Targets	Target Name and Biological Evidence	ClinicalTrials.gov Registration	Public
Clinical Phase	Phase I/II/III and Enrollment Status	Clinical Trial Registration	Public
AI Contribution Description	The Specific Role of AI in Molecular Design	Company Announcements or Papers	Partially Public
Control Design	Control Group and Primary Endpoint	Clinical Trial Protocol	Partially disclosed
Effect Size	Clinical Effect Size	Conference Presentation or Paper	Limited
Cost comparison	Baseline Comparison with Conventional Methods	Company Annual Reports or Industry Reports	Rarely Published

 3. AI in clinical trials must first demonstrate the reliability of the tool before efficiency improvements can be discussed

 Industry reports indicate that the FDA and EMA have officially approved or recognized several AI-driven clinical analysis tools, such as PathAI’s AIM-NASH tool foradjunctive diagnosis of liver biopsy pathology; major pharmaceutical companies like Pfizer have also extensively incorporated AI into more than half of their clinical trials for patient screening and adverse event prediction. This information is sourced from industry reports and must be verified against FDA public documents, EMA assessment reports, corporate announcements, or peer-reviewed materials when formalizing this text.This section focuses on three use cases—patient screening, adverse event prediction, and digital pathology—and distinguishes between AI tools used for research purposes and those incorporated into formal decision-making processes.

 Table 3-1: Three Categories of AI Tool Use Cases in Clinical Trials

Use Case	Typical Applications	Current Status	Research Questions to Be Addressed
Patient Screening	Predicting Enrollment Suitability Based on EHR Data	Used by some pharmaceutical companies, mostly for research purposes	Representativeness of the training population and external validation
Adverse Event Prediction	Predicting Toxicity Risk in Specific Patients	Deployed by pharmaceutical companies such as Pfizer in some trials	Are the action pathways clear, and what are the consequences of underreporting?
Digital Pathology	Scoring of Liver Fibrosis and Steatosis	PathAI’s AIM-NASH Receives Regulatory Approval	Inter-laboratory consistency, review by pathology experts

 The table above lists typical applications and current statuses across three scenarios. It should be noted that “adoption by pharmaceutical companies” does not equate to “regulatory approval,” and “investigational use” does not equate to “inclusion in formal decision-making.”The statement in the news report that “Pfizer has introduced AI in more than half of its clinical trials” should be verified in official documents, such as Pfizer’s public announcements or annual reports, to clarify the specific types of trials, the types of AI applications, and how the adoption rate was calculated. Similarly, the scope of regulatory approval for the PathAI AIM-NASH tool should be based on the FDA’s public documents to confirm that the approval applies to specific uses rather than general AI pathology.

 3.1 Patient Screening Must Prevent Models from Introducing Historical Bias into Trials

 The application of AI in patient screening typically relies on electronic health record (EHR) data, using models to predict which patients are more likely to meet enrollment criteria or respond to treatment. The risk with this approach is that if historical biases exist in the training data—for example, if certain populations were systematically excluded from past trials—the model will learn these biases as correct answers and amplify them in new screening processes.

 When evaluating AI patient screening tools, the following dimensions must be examined: Representativeness of the training population—from which hospitals and regions does the training data come, and which racial groups and age groups does it cover? If the training data primarily comes from a cohort dominated by white males, the model’s predictive performance for other populations may decline. Handling of missing data—missing values are common in EHR data; how does the model handle them?Are they directly deleted, imputed, or treated as features in themselves? Different handling methods have a significant impact on predictive results. External validation: Has the model been validated on cohorts outside the training center? If it performs well only at the development center, the model’s generalization ability is questionable. Performance differences across centers: Does the model perform consistently at academic medical centers, community hospitals, and international centers? Characteristics of those excluded—what common characteristics do patients excluded by the model share? Are these exclusions justified?

 Efficiency gains must not come at the expense of narrowing the representativeness of the population. If an AI screening tool improves enrollment efficiency by excluding specific groups, it is effectively creating new biases. This practice poses serious ethical and regulatory risks—the FDA’s requirements for the representativeness of clinical trial populations are becoming increasingly stringent, and the systematic exclusion of underrepresented groups by AI systems may result in trial results being rejected.

 3.2 Adverse Event Prediction Must Specify Who Takes What Action and When

 The output of an AI adverse event prediction tool is typically a risk score—for example, the probability that a patient will experience a serious adverse event within the next 7 days. However, the risk score itself has no clinical value; it must correspond to a clear course of action: who takes what action based on this score, and when.

 A usable AI adverse event prediction system should be able to answer the following questions: What action is triggered when the risk score reaches a certain threshold—is it increased monitoring frequency, dose adjustment, or suspension of treatment and initiation of a clinical review? Who approves the recommended actions—the attending physician, the research nurse, or an independent Data Safety Monitoring Board? How are false positives handled?If the model incorrectly predicts an adverse event, leading to unnecessary dose adjustments or suspensions, what impact will this have on trial progress and the patient experience? How are the consequences of missed events tracked? If the model fails to predict an adverse event that actually occurs, is there a mechanism to investigate the cause and improve the model? Are these actions documented—is every action taken based on the model’s recommendation recorded in the clinical trial management system to form an auditable decision chain?

 Table 3-2 Evaluation of Action Pathways for AI Adverse Event Prediction Tools

Evaluation Dimensions	Acceptance Criteria	Non-Compliant Performance	Consequences
Action Trigger	Clear risk thresholds and corresponding action plans	Provides only a risk score without action recommendations	Prediction results cannot be translated into clinical value
Approval Authority	Clearly defined approval authorities and review processes	Vaguely stated as being at the discretion of the physician	Unclear accountability and no record of decision-making
False Positive Management	Assessment of the impact of false positives and mitigation measures	Consequences of false positives are not discussed	Unnecessary interventions affect the trial
Tracking of Underreporting	Mechanisms for reviewing underreporting incidents and improving models	No analysis of missed events	Model flaws persist
Audit Log	Every model-based decision is logged	Decisions Are Not Linked to Model Outputs	Failure to Meet Regulatory Audit Requirements

 Predictions without a clear course of action are difficult to translate into clinical value. An AI system that only outputs risk scores without explaining how to use them can, at best, be considered a statistical tool—it cannot be integrated into the formal decision-making process of clinical trials. A true AI-based adverse event prediction system should be a comprehensive framework that includes a model, action plans, an approval process, and audit records.

 3.3 AI-Assisted Pathology Requires Reproducible, Traceable Human-Machine Collaboration

 AI applications in digital pathology include histological scoring, fibrosis staging, and tumor region identification. The PathAI AIM-NASH tool mentioned in the article is a specific example—it is used to assist with pathological scoring of liver biopsy specimens from patients with non-alcoholic steatohepatitis (NASH).When evaluating such tools, the following dimensions should be considered: Scan standardization—Are the resolution, color calibration, and image quality consistent across different digital pathology scanners? Staining consistency—Do differences in staining protocols between laboratories affect algorithm performance? Algorithm version management—Are version numbers, changes to training data, and performance variations documented with each model update?Review by pathology experts—Are AI results reviewed by pathology experts? How are discrepancies in reviews handled? Cross-laboratory consistency—Are the algorithm’s results reproducible across different laboratories?

 The scope of regulatory approval must be described in terms of the specific tool and intended use; it must not be generalized as “AI has been accepted by regulators.”The approval of the PathAI AIM-NASH tool refers specifically to its use for pathological scoring of NASH liver biopsies; it cannot be generalized to imply that the FDA has fully accepted the general application of AI in pathological diagnosis. When citing such regulatory approvals in formal documents, the following must be clearly stated: the approving authority (FDA or EMA), the name of the approved tool, the specific intended use, the approval date, and the document number.

 Recommendations for Action: When listening to presentations on AI pathology tools, attendees should ask three questions: First, what is the scope of the tool’s regulatory approval—is it for investigational use,adjunctive diagnosis, or independent diagnosis? Second, where is the data on consistency across different laboratories using the tool—are there any results from multicenter validation studies?Third, what is the process for resolving discrepancies between pathology experts and AI results—who has the final say? If the presenter cannot answer these questions, the tool should be classified as a “proof of concept” rather than a “deployed tool.”

 From a regulatory policy perspective, in 2024, the FDA issued a draft guidance on Planned Change Control Plans (PCCPs) for AI/ML-driven software as medical devices, requiring that AI models have predefined change control procedures in place for any changes occurring after deployment. This framework is equally relevant for AI tools in clinical trials. If a model continues to learn or update in a production environment, companies must define in advance the scope of acceptable changes, validation requirements, and rollback mechanisms.The EMA is also discussing regulatory pathways for AI throughout the full lifecycle of medicinal products under its AI Working Group framework, but has not yet developed detailed guidance similar to that of the FDA. When attendees encounter regulatory-related discussions on the BPI agenda, they should pay close attention to the latest statements from regulatory agency representatives regarding evidence requirements for AI tools, particularly specific expectations concerning the definition of intended use and change control.

 Another question worth exploring is whether pharmaceutical companies’ internal decision-making processes for adopting AI tools align with regulatory expectations. In many pharmaceutical companies, the procurement and deployment of AI tools are led by IT or digital teams, while the involvement of quality teams often lags behind. This process may result in AI tools entering clinical or production workflows without undergoing quality review, requiring significant retroactive work when compliance gaps are discovered later.It is recommended that pharmaceutical companies establish an access review mechanism for AI tools, whereby quality, regulatory, and process teams jointly evaluate the tool’s intended use, validation requirements, and compliance risks prior to procurement.

 Distinguishing between Research Use Only (RUO) and In Vitro Diagnostic (IVD) applications is another dimension of evaluating clinical AI tools. Many AI analytics tools initially enter the market with an RUO label and apply for IVD certification after accumulating validation data.RUO tools cannot be used for clinical decision-making—their results cannot serve as the basis for patient enrollment or treatment adjustments. If an AI tool is deployed in a clinical trial for patient screening or adverse event prediction but is labeled only as RUO, this poses a compliance risk. When evaluating AI clinical tools, participants should confirm the tool’s regulatory status—whether it is RUO, IVD, or an Investigational Device Exemption (IDE)—and verify that this status aligns with its actual intended use.

 Table 3-3 Comparison of Regulatory Pathways for AI Clinical Tools

Tool Type	Regulatory Pathway	Evidence Requirements	Typical Timeline
Research Use Only (RUO)	No approval required	Internal Validation	Several months
Diagnostic Aids	FDA 510(k) or De Novo	Clinical validation data	1 to 2 years
Standalone Diagnosis	PMA Application	Clinical trial data	2 to 3 years
Companion diagnostic	CDx Approval	Validation in Conjunction with the Drug	In parallel with the drug

 4. The core of digital biomanufacturing at the boston bio conference is not prediction, but turning predictions into controlled actions

 This is the core section of the full text. The criteria for evaluating digital biomanufacturing lie in whether a model can link critical process parameters (CPPs) to critical quality attributes (CQAs) and adjust operations within defined process boundaries; predictive accuracy itself is merely a fundamental prerequisite. Focusing on cell culture, downstream purification, process analytical technology (PAT), deviation detection, and scale-up, this section assesses whether a model has truly been integrated into the production process or remains confined to demonstration data.

 BPI’s digital biomanufacturing agenda typically includes topics such as digital twins, process monitoring, and automated control. While these topics sound technologically advanced, the evaluation criteria should return to the fundamental questions of manufacturing: Have the model’s predictions led to actual operational changes?Is this change within validated parameters? Are the results of the change documented and audited? If the answer to all three questions is “yes,” then the AI system has been integrated into a controlled process; if the answer to any one question is “no” or “unsure,” then it remains in the auxiliary analysis phase.

 Table 4-1: Maturity Levels for AI Applications in Digital Biomanufacturing

Maturity Levels	Characteristics	Whether Integrated into Controlled Processes	Validation Requirements
L1 Data Visualization	Displays process data and trends; no predictive capabilities	No	Basic Data Integrity
L2 Anomaly Detection	Identifies data points deviating from the normal range; provides alerts	Some require manual judgment	Alert Threshold Validation
L3 Predictions and Recommendations	Predict future trends and provide operational recommendations	No—recommendations are not automatically executed	Prediction Performance Validation
L4 Controlled Adjustment	Automatically adjusts process parameters within the validated range	Yes	Complete validation package with change control
L5 Adaptive Optimization	The model continuously learns and optimizes the process	Yes Strict change management required	Model Lifecycle Management

 The table above defines the five maturity levels for AI applications in digital biomanufacturing. Most AI applications claiming to be “digital biomanufacturing” currently fall between Levels 2 and 3—they can detect anomalies and provide recommendations but have not yet entered automated control processes. Levels 4 and 5 require a comprehensive validation package, change control, and model lifecycle management, and remain rare in the biopharmaceutical industry at present.When evaluating vendor solutions, attendees should clarify which level the vendor is at to avoid situations where L2 anomaly detection is marketed as L4 controlled adjustments.

 4.1 Real Production Data Tests Models Better Than Demonstration Data

 A model that performs well on clean historical data may not necessarily handle missing values and anomalies encountered in actual production environments. This is the first key question in evaluating AI systems for digital biomanufacturing: What are the sources of the training and testing data?

In biopharmaceutical manufacturing, data sources can be divided into four categories: development experimental data, derived from small-scale experiments during the process development phase, where conditions are controlled but differ from production scale; engineering batch data, derived from engineering runs during the scale-up phase, which are close in scale to production but where stability is still being optimized;GMP production data, derived from batches in formal commercial production, which offers the highest data quality but is difficult to obtain and has a limited sample size; and deviation investigation data, supplementary data from investigations of abnormal events, which includes operating conditions that would not occur during normal operations. Data from different sources pose varying degrees of challenge to the model—a model trained solely on development experiment data may be unable to handle sensor drift, batch-to-batch variations, and abnormal operating conditions encountered in GMP production.

 Table 4-2: Degree of Challenge for AI Models from Different Data Sources

Data Source	Data Characteristics	Challenge to the Model	Common Issues
Development and Experimentation	Limited Controllable Variables	Low	Significant gap from production scale
Engineering Batch	Stability during the scale-up phase is still being fine-tuned	Medium	Small number of batches; incomplete operating conditions
GMP Production	Full-scale production with high-quality data	High	Restricted access; limited sample size
Deviation Investigation	Abnormal operating conditions; non-standard operations	Extremely high	Data sparsity; difficulty in annotation

 When evaluating a supplier’s AI model, ask the following questions: How many batches did the training data come from? If there are only a few dozen batches of development and experimental data, the model’s statistical foundation is very weak. Does it include abnormal batches and biased data? If the training set consists only of normal operating batches, the model’s performance when encountering anomalies cannot be predicted.How is sensor data quality handled? In production, sensors may drift, malfunction, or generate noise—does the model have mechanisms to address these issues? How is process drift identified and accounted for? Cell metabolism during cell culture drifts over time—can the model adapt to this drift?

 4.2 For AI recommendations to be incorporated into SOPs, clear authorization and fallback mechanisms are required

 For AI model recommendations to be incorporated into Standard Operating Procedures (SOPs), three issues must be clearly defined: Does the model provide prompts, suggest adjustments, or perform automatic control? Who has the authority to approve operational changes based on the model’s recommendations? When must manual intervention occur? These three issues constitute the authorization and fallback framework for AI integration into controlled processes.

 In a GMP production environment, any operational change requires validation and approval. If an AI model’s recommendation serves only as a reference for operators—for example, alerting them to monitor metabolic abnormalities in the current batch—then it does not constitute a formal operational change, and the model itself does not need to be incorporated into the SOP. However, if the AI model’s recommendation leads to actual operational adjustments—such as a suggestion to reduce the feed rate—then this recommendation must be approved by the quality department, become part of the SOP, and be documented in the batch production record.

 How to return to a validated state following an anomaly is another critical question that must be addressed. If an operational change recommended by the AI model leads to abnormal results—such as a decline in product quality or a batch failure—the production system must be able to revert to validated standard operating procedures. This means that operational changes suggested by the AI model must have a clear fallback path: under what conditions the system automatically reverts, who approves the fallback, and how affected batches are handled after the fallback.Avoid equating a high degree of automation directly with compliance maturity—a system capable of automatic control but lacking a rollback mechanism poses a greater risk than a system that only provides recommendations but has a well-defined rollback process.

 Table 4-3: Authorization and Fallback Framework for Incorporating AI Recommendations into SOPs

Control Level	Model Role	Approval Requirements	Fallback Mechanism	Documentation Requirements
Prompts	Information Provided for Reference	No Additional Approval Required	No rollback required	Record Prompt Content
Suggested adjustments	Recommended changes to operating parameters	Quality Department Review	Can be manually overridden	Record recommendations and approval decisions
Controlled automatic adjustment	Automatic adjustments within the validation scope	Validation package with change control approval	Automatically revert to baseline parameters	Complete audit trail
Adaptive optimization	Continuous learning and optimization	Model lifecycle management	Rollback to the previous validated version	Change Log with Re-validation

 4.3 Model Changes Also Require Lifecycle Management

 Models capable of continuous learning can actually increase uncertainty in the quality system if they lack a controlled update mechanism. Lifecycle management for model changes includes the following dimensions: Version Management—Are the version number, details of the changes, and reasons for the changes recorded with each model update? Training Data Management—What new content is included in the training data for the new model version? Have new data sources been introduced? Performance Thresholds—Do the performance metrics of the updated model meet the preset thresholds?If not, is the model rolled back to the previous version? Drift Monitoring—Does the model’s predictive performance in production drift over time? Are there mechanisms in place to detect and alert on such drift? Re-validation—Is performance qualification (PQ) required after a model update? Access Control—Who has the authority to modify model parameters? Do modifications require dual review? Audit Trail—Are all model changes recorded and available for inspection?

 These dimensions constitute the basic framework for model change lifecycle management. In a GMP environment, AI models should be regarded as computerized systems and must comply with the requirements of computerized system validation guidelines such as GAMP 5. When vendors promote continuous learning or adaptive optimization features without simultaneously providing change management and revalidation plans, these features may actually pose compliance risks. When evaluating vendor solutions, attendees should request that vendors provide standard operating procedures for model change management and samples of change logs.

 Action Recommendation: Participants in the Digital Biomanufacturing agenda should prepare an evaluation checklist covering four dimensions: data source validation, control level determination, access permissions and fallback mechanisms, and model change management. Prepare 3–5 specific questions for each dimension to ask vendors at their booths or during the Q&A sessions.Prioritize suppliers that can provide a complete validation package and change control documentation over those that merely present predictive performance metrics. When reviewing the information after the event, categorize the collected case studies according to the L1–L5 maturity levels to avoid mistaking L2 anomaly detection for L4 controlled adjustments.

 The implementation status of Process Analytical Technology (PAT) is also an important benchmark for assessing the maturity of digital biomanufacturing. The goal of PAT is to achieve real-time release testing, but actual deployment faces challenges such as sensor drift, multivariate model validation, and data integrity.The role of AI models within the PAT framework should be to assist in understanding the sources of process variability, rather than to replace release testing methods. If an AI model claims to replace traditional release testing, it must provide validation data that is equivalent to or superior to traditional methods, including a comprehensive evaluation across dimensions such as specificity, accuracy, precision, and robustness.

 Digital twins are another frequently mentioned concept, but their actual deployment in biopharmaceuticals remains limited. A true digital twin requires real-time synchronization of physical process data, continuous updating of model parameters, and the ability to predict trends in process deviations.Currently, most systems labeled as “digital twins” are in fact merely visual dashboards for process data or offline simulation models—they lack real-time data synchronization, predictive validation, and closed-loop connectivity with operational controls. When evaluating digital twin solutions, attendees should inquire about data update frequency, the results of model prediction validation, and the degree of integration with SOPs.

 Data infrastructure is a fundamental prerequisite for digital biomanufacturing, but many pharmaceutical companies only discover infrastructure deficiencies when deploying AI models. Specifically, production data is scattered across different systems (MES, LIMS, ERP, historian) in inconsistent formats; sensor data suffers from missing values and noise, with no preprocessing workflows; batch records are primarily in paper or PDF format, with low levels of structuring; and historical data is not archived in accordance with GMP requirements, resulting in insufficient traceability.Unless these issues are addressed first, AI models will lack reliable data inputs. It is recommended that pharmaceutical companies conduct a data maturity assessment before introducing AI tools—scoring across four dimensions: data completeness, structuring, traceability, and cross-system connectivity—to identify infrastructure areas requiring priority improvement.

Another practical challenge is cross-departmental collaboration. Digital biomanufacturing involves multiple departments, including process, quality, IT, validation, and regulatory affairs, each of which has different priorities regarding AI models. Without a clear cross-departmental governance mechanism—such as who leads model evaluation, who approves deployment, and who is responsible for ongoing monitoring—the deployment of AI tools can easily fall into a vacuum of responsibility between departments. It is recommended that pharmaceutical companies establish cross-departmental working groups and decision-making mechanisms before advancing digital biomanufacturing projects, clearly defining the roles and responsibilities of all parties.

 5. CMC and Regulatory Authorities Focus Not on Algorithm Terminology, but on Whether the Chain of Evidence Is Closed

 In CMC (Chemistry, Manufacturing, and Control) and regulatory reviews, the evaluation criteria for AI tools do not hinge on the specific algorithm used—whether it is deep learning, random forests, or statistical models—but rather on whether the chain of evidence is closed. A closed chain of evidence means that every step—from data input, model processing, and output results to quality decisions—has traceable records and verifiable logic.

 Do not claim that regulatory authorities have approved the general use of a certain type of AI. Both the FDA and EMA grant approvals for AI tools on a product-specific and indication-specific basis—for example, the use of a specific tool for pathologicaladjunctive diagnosis in a particular indication. Such approvals cannot be generalized to mean that “the FDA has accepted the general application of AI in drug development.” In formal documentation, references must be made to specific product names, detailed descriptions of intended uses, and official document numbers.

 Table 5-1: Check for the Closure of the AI Tool Evidence Chain

Evidence Component	Questions to Be Answered	Closure Criteria	Common Gaps
Data Integrity	Data Source Quality Traceability	Data has an audit trail with verifiable sources	Unknown source of training data
Model Explainability	How the model arrives at its predictions	Interpretable Predictors	Black-box models offer no explanation
Intended Use	What specific decisions is the model used for?	Clear and well-defined purpose	Vague description of purpose
Validation Approach	How to Validate Model Performance	There is a validation plan, a threshold, and results	Only provides ROC curves
Quality Risk Management	Impact Assessment of Model Failure	Risk assessment and mitigation measures	Consequences of failure not assessed

 5.1 The model must specify which key quality attributes it affects

 The predictive results of an AI model must be linked to specific product quality attributes—purity, aggregates, glycosylation, potency, or other product-specific quality attributes. If the model only improves equipment efficiency—for example, by increasing bioreactor utilization—without affecting product quality, its use should be accurately limited to equipment efficiency optimization and should not be presented as a quality improvement.

 In biopharmaceuticals, critical quality attributes include, but are not limited to: protein aggregate levels—which affect immunogenicity and safety; glycosylation profiles—which affect potency and half-life; host cell protein residues—which affect safety; charge variants—which affect potency and stability; and particulate matter—which affects safety and the administration experience.If an AI model can predict deviation trends for any of these CQAs, it establishes a direct link to product quality. However, if the model only predicts equipment parameters—such as temperature, dissolved oxygen, or pH—without further linking these parameters to how they affect CQAs, the model’s value remains limited to process monitoring and does not constitute support for quality decision-making.

 Table 5-2 Evaluation Framework for Linking AI Models to CQAs

Level of Linkage	Model Output	Relationship to CQA	Intended Use
L1 Process Parameters	Predict trends in temperature, dissolved oxygen, and pH	Indirect; requires further analysis	Process Monitoring
L2 Process Attributes	Predicted trends in metabolites and cell density	Partially relevant	Process Understanding
L3 Product Quality	Predicting Aggregate Glycosylation Efficacy	Directly Related	Quality Decision Support
L4 Release Support	Predicting Batch Acceptance or Rejection	Direct Decision-Making	Release assistance requires manual confirmation

 The table above defines the four levels of integration between AI models and CQA. When evaluating AI tools related to CMC, attendees should inquire about the specific integration level of the model. If a supplier can only demonstrate Level 1 process parameter prediction but their promotional materials imply Level 3 or Level 4 quality decision-making capabilities, this constitutes exaggerated claims.

 5.2 Supplier Algorithms Must Not Be a “Black Box” in the Quality System

 When pharmaceutical companies procure AI algorithms from suppliers, the convenience of the algorithm cannot replace the company’s responsibility for final quality decisions. Supplier algorithms must not become a “black box” within the quality system—pharmaceutical companies must be able to answer the following questions: Data Ownership—Who owns the data used to train the model? Is the pharmaceutical company’s production data used by the supplier to train models for other clients?Model Access—Can the pharmaceutical company view the model’s internal structure and parameters, or is access limited to API calls? Change Notifications—Does the supplier notify the pharmaceutical company in advance when updating the model? Does the pharmaceutical company have the right to reject updates? Validation Responsibility—Is model validation the responsibility of the supplier or the pharmaceutical company? Cybersecurity—How are cybersecurity risks associated with the model’s deployment managed? Business Continuity—If the supplier ceases operations or discontinues support for the product, how will the pharmaceutical company maintain production?

 These issues have long existed in the procurement of traditional computerized systems, but AI algorithms add a new dimension: the model’s “learning” capability means that validation is not a one-time process. If the model continues to learn, validation must also be ongoing. When procuring AI algorithms, pharmaceutical companies should clearly stipulate in their quality agreements the obligations regarding notification of model changes, the allocation of validation responsibilities, and business continuity safeguards.The convenience of purchasing off-the-shelf software cannot replace a pharmaceutical company’s responsibility for final quality decisions; this is a fundamental principle of GMP and a common checkpoint in regulatory audits.

 5.3 Communication with Regulators Should Begin with the Intended Use

 When communicating with regulatory authorities about AI tools, the discussion should begin with the intended use, rather than with algorithm performance. The intended use determines the level of evidence required: models used for exploratory analysis require less validation evidence; models used for monitoring require proof of the reliability of alerts; models used to support product release require a complete validation package and change control; and models used for automated control require the highest level of validation and continuous monitoring.

 The value of early communication lies in avoiding the accumulation of regulatory debt later on. If a pharmaceutical company fails to clarify a model’s intended use during the early stages of development and only discovers at the submission stage that regulatory requirements do not align with actual deployment, it will need to retroactively supplement a large amount of validation data or even redesign the model. It is recommended to engage in preliminary communication with regulatory authorities early in the model development process—through the FDA’s Pre-IND meetings, Type C meetings, or the EMA’s Scientific Advice procedure—to clarify the types of evidence and validation standards expected by regulators.

 Table 5-3 Evidence Strength Requirements for Different Intended Uses

Intended Use	Evidence Requirements	Change Management	Timing of Regulatory Communication
Exploratory Analysis	Data Integrity	Low Requirements	No prior communication required
Process Monitoring	Alarm Threshold Validation False Positive Assessment	Threshold changes must be documented	Recommend Early Communication
Release Support	Comprehensive validation package with change control	Strict Change Management	Pre-IND or Type C meetings
Automated controls	Highest-Level Validation with Continuous Monitoring	Model Lifecycle Management	Early Communication

 Action Recommendation: Prior to the meeting, the quality and regulatory teams should prepare a list of intended uses, detailing the AI tools the company is currently using or plans to deploy, along with their intended uses. During the BPI agenda, focus on regulatory-related discussions and gather the latest statements from regulatory representatives regarding evidence requirements for AI tools. After the meeting, review the list to confirm whether the evidence for the company’s existing tools meets regulatory expectations and identify any validation data that needs to be supplemented.

 From the perspective of ICH guidelines, the application of AI tools in CMC requires reference to multiple guideline frameworks. ICH Q8 (Drug Development) mandates quality by design, requiring the definition of Critical Quality Attributes (CQAs) and design space during the design phase—if an AI model is used to support the establishment of design space, its predictive results must be included in the design space justification dossier. ICH Q9 (Quality Risk Management) requires a risk assessment of tool failures—the failure modes, impacts, and severity of AI models should be systematically evaluated.ICH Q10 (Quality Management Systems for Medicinal Products) mandates change management—any changes to AI models must go through the change control system. ICH Q12 (Life Cycle Management) provides a framework for post-marketing changes. If an AI model is continuously updated throughout the product life cycle, the life cycle management requirements of Q12 must be followed. While these guidelines were not developed specifically for AI, their frameworks are applicable to the compliant deployment of AI tools.

 When preparing regulatory communication materials, pharmaceutical companies should organize the evidence for AI tools according to five dimensions: “Data, Model, Validation, Deployment, and Monitoring.” The Data dimension describes the source, quality, and representativeness of training and test data; the Model dimension describes the algorithm type, interpretability, and limitations; the Validation dimension describes performance metrics, thresholds, and external validation results; the Deployment dimension describes the intended use, operating environment, and permission settings;the monitoring dimension describes drift detection, alerts, and revalidation plans. This five-dimensional organizational approach helps regulatory reviewers quickly understand the complete evidence chain for the AI tool, reducing information asymmetry during the review process.

 When preparing for pre-submission meetings with regulatory authorities, pharmaceutical companies should prepare a “Model Summary Document” that includes: the model name and version; a description of the intended use; an overview of the algorithm type (without disclosing trade secrets, but specifying the level of interpretability); the source and scale of training data; the validation protocol and results; known limitations and failure modes; and a change control plan.This document does not need to include the complete code or parameters, but it must enable regulatory reviewers to understand the model’s scope of use and risk characteristics. The goal of the pre-submission meeting is to confirm evidence requirements and communication strategies to avoid rework later due to misalignment; regulatory approval is a separate process that occurs during the subsequent formal submission phase.

 Pharmaceutical companies should also note that regulatory agencies have different review pathways for different types of AI tools.AI tools used in the drug discovery phase typically do not require regulatory approval; however, if their outputs are used to support the IND submission package, the traceability of data generation must be ensured. AI tools used in clinical trials, if used as medical devices, must follow the medical device approval pathway. AI tools used for production quality decisions are managed through validation and change control within the GMP system and submitted as part of the process and control strategies during product registration. Confusing these pathways may lead to misdirected regulatory communications.

 6. CGT and Complex Biologics Best Highlight the Limits of AI’s Capabilities

 Cell and gene therapy (CGT) products are characterized by significant batch-to-batch variability, complex potency testing, short shelf lives, and high supply chain pressures. These characteristics make CGT a high-value application scenario for digital tools, as well as the scenario where limited data volume and challenges with comparability are most pronounced.In CGT, the limitations of AI are most clearly exposed—when sample sizes are small, data heterogeneity is high, and analytical methods are immature, the advantages of complex models often fail to materialize and may instead create a false sense of certainty.

 Table 6-1 Challenges of AI Applications in CGT Products

CGT Characteristics	Impact on AI	Data Challenges	Recommended Strategies
Significant Batch Variability	High Heterogeneity in Model Training Data	Need for data from multiple cohorts, but acquisition is difficult	Prioritize the use of interpretable statistical models
Complex Efficacy Testing	High uncertainty in the output variable	High variability in efficacy testing itself	Refine the assay before building the model
Short shelf life	High demand for real-time decision-making	High requirements for data timeliness	Focus on rapid analysis models
Limited sample size	Complex models are prone to overfitting	Traditional statistical methods may be more appropriate	Avoid overparameterization
High supply chain pressure	Time constraints affect model deployment	Requires fast and reliable forecasts	Prioritize deploying mature tools

 6.1 Avoid Using Complex Models to Create a False Sense of Certainty Under Small-Sample Conditions

 In the CGT context, the annual production batches for a single product may number only a few dozen or even just over a dozen. With such a small sample size, complex models—such as those based on deep learning—are prone to overfitting: they may perform perfectly on the training data but fail to make accurate predictions on new batches. Explainable statistical models are sometimes more suitable for regulated decision-making than highly complex models because their assumptions are more transparent, their limitations are clearer, and their validation requirements are more controllable.

 When evaluating AI models under small-sample conditions, the following should be examined: cross-batch validation—has the model undergone leave-one-out or cross-validation across different batches? Cross-site validation—if the product is manufactured at multiple sites, does the model perform consistently across them? Cross-platform validation—if different analytical platforms are used, are the model results comparable? Confidence intervals—are the confidence intervals of the model’s predictions reasonable?Under small-sample conditions, overly narrow confidence intervals are often a sign of overfitting. Scope of applicability: Does the model clearly specify the conditions under which it is applicable and those under which it is not?

 6.2 AI Cannot Replace Immature Analytical Methods

 If the original testing methods cannot reliably reflect a product’s identity, purity, potency, and safety, AI models will only amplify measurement noise. This is a fundamental limitation of AI applications in CGT: many potency testing methods for CGT products are not yet sufficiently mature. For example, the coefficient of variation (CV) for cell potency testing may exceed 30%. AI models built on such a foundation merely reflect the variability of the testing method rather than the product’s true biological characteristics.

 The correct approach is to first establish reliable analytical methods before discussing multivariate prediction. This means that before investing in AI model development, methodological validation of the analytical method—including specificity, accuracy, precision, linear range, limit of quantification, and robustness—must be completed. If methodological validation is not passed, any predictions made by an AI model based on that method lack a solid foundation.When attending presentations on AI applications related to CGT, participants should inquire about the coefficient of variation of the analytical method and the status of its methodological validation. If the presenter cannot answer these questions, the predictive results of their AI model lack credibility.

 6.3 Automation Must Simultaneously Address Closed-System Integration, Logistics, and Variations in Manual Operations

 Automation in CGT is not merely the success of a single algorithm—it requires simultaneously addressing coordination issues across multiple stages, including closed-system equipment integration, cold-chain logistics management, electronic batch records, and sample tracking. Do not equate the success of a single algorithm with the digitization of end-to-end manufacturing.

 Specific aspects of CGT automation include: Equipment integration—Can closed-system equipment from different vendors (such as cell processors, perfusion systems, and cryopreservation equipment) achieve data interoperability? Electronic batch records—Can operational data during the production process be automatically collected and linked to batch records? Sample tracking—Is the identity of the entire chain traceable from collection to reinfusion?Exception Handling—When automation equipment malfunctions, are the procedures for manual intervention clearly defined? If automation is not achieved in any of these stages, the entire process cannot be considered end-to-end digitalization.

 Action Recommendations: Attendees involved in CGT should pay close attention to BPI’s Cell and Gene Therapy agenda, focusing on gathering the following information: case studies of AI applications in existing CGT products, including their data sources, the validation status of analytical methods, and the scope of automation coverage. After the conference, organize these case studies into three categories—“single-point applications,” “partial process coverage,” and “end-to-end integration”—to avoid overinterpreting single-point applications as process digitization.

 Take CAR-T cell therapy as an example: testing the product’s quality attributes presents multiple challenges. Efficacy testing typically employs target cell killing assays or cytokine release assays, and the coefficient of variation for these biological assay methods alone can reach 20% to 40%.Given this level of testing precision, if an AI model claims to predict efficacy deviations, its prediction error must be smaller than the inherent variability of the testing method itself; otherwise, the model’s predictions have no practical significance—they merely replicate testing noise. When listening to reports on AI applications related to CGT, attendees should inquire about the coefficient of variation of the analytical methods; if the coefficient of variation exceeds 15%, the reliability of the model’s predictions must be assessed with caution.

 Another issue requiring attention is comparability studies for CGT products. When process changes occur—such as switching cell culture substrates, adjusting transfection parameters, or changing raw material suppliers—comparability studies are required to demonstrate that product quality remains equivalent before and after the change.If AI models are used to support comparability studies, they must be capable of processing limited batches of data from before and after the change and providing statistically reliable equivalence assessments. Under small-sample conditions, traditional equivalence tests (such as TOST) may be more suitable for comparability assessments than complex AI models, as their assumptions and limitations are more transparent.

 Take viral vector production as an example; the unique nature of this process poses additional challenges for AI applications. Viral vector production typically employs suspension or adherent culture, and the sensitivity to process parameters varies greatly between these two culture methods. Downstream purification involves multiple filtration and chromatography steps, and the recovery rate at each step affects the final yield. Since viral vector products are often key raw materials for personalized therapies (such as in vivo gene therapy), batch yield directly impacts patient access to medication.If AI models are used for viral vector process optimization, they must address multiple challenges, including a large number of process steps, complex parameter interactions, and limited data availability. When reviewing relevant case studies, attendees should inquire about which steps in the process chain the model covers and whether the validation data for each step is complete.

 The application of AI in plasmid DNA production also presents a unique scenario.As a raw material for gene therapy or an active ingredient in DNA vaccines, plasmid DNA production is relatively mature (E. coli fermentation), but quality control involves multiple dimensions, including supercoiling ratio, residual host DNA, and endotoxins. If an AI model can predict trends in the supercoiling ratio, it can help process teams adjust induction conditions in advance during fermentation, thereby reducing the burden on downstream purification. However, such predictions must be based on a stable fermentation process and reliable analytical methods.

 Table 6-2 Reference Coefficients of Variation for CGT Product Analytical Methods

Test Item	Typical Coefficient of Variation	Acceptable Upper Limit	Impact on AI Models
Cell Assay	20% to 40%	25%	Prediction error must be less than the detection limit
Purity Assay (HPLC)	5% to 15%	10%	Can be used for quality trend forecasting
Retention of host proteins	10% to 25%	15%	Affects safety profile prediction
Viral titer	15% to 30%	20%	Affects the reliability of yield predictions
Identification	Qualitative	Qualitative	Not applicable to quantitative forecasting

 7. Different attendees should come to the boston bio event with questions regarding supplier elimination strategies

 BPI’s booth and agenda provide attendees with opportunities to engage directly with AI vendors. However, attendees in different roles have distinct priorities: process teams assess whether models improve development and scale-up; quality and regulatory teams evaluate whether evidence is audit-ready; business development and management assess deployment costs and reusability; and AI vendors must demonstrate real-world performance. This section provides a list of questions each role should prepare for the event.

 Table 7-1 Evaluation Focus Areas for Different Roles

Role	Key Considerations	Priority Information	Criteria for Eliminating Options
Engineering Team	Whether the model has been improved Development and Scale-up	Training Batch Sources Anomalous Batch Performance Cross-Scale Data	Inability to provide failure cases
Quality Team	Can the evidence be audited?	Validation package change control audit trail	Unable to present validation documentation
Regulatory Team	Is the Intended Use Clearly Defined?	Records of Communication with Regulators Evidence Strength Matching	Ambiguous Intended Use
BD Management	Deployment Costs and Reusability	Breakdown of Total Costs Cross-Product Reuse Plan	Lack of Cost Transparency

 7.1 Process teams require raw data and failure cases first

 When evaluating AI vendors, the first question the process team should ask is, “Which batches did your training data come from?” Model accuracy is only a secondary concern. Specifically, they should inquire: How many batches did the training data come from? How many abnormal batches were included? How does the model perform across scales (from lab to pilot to production)? Under what circumstances has the model failed? What is the frequency of human intervention, and what are the reasons for it?

 Listing only best-case scenarios is insufficient to support on-site adoption. If a vendor can only provide success stories—handpicked batches and predictions under ideal conditions—the model’s performance in actual production cannot be predicted. The process team should require the vendor to provide performance data for the model on abnormal batches, including false positive rates and false negative rates. If the vendor refuses to provide this data, the solution should be classified as “proof of concept” and excluded from the list of candidates for on-site deployment.

 7.2 Quality Teams Should Review Validation Packages and Change Control First

 When evaluating an AI vendor, the quality team should review the following documents: User Requirements Specification (URS), Risk Assessment (RA), Design Qualification (DQ), Installation Qualification (IQ), Operational Qualification (OQ), Performance Qualification (PQ), audit trail records, access control policies, version change logs, and revalidation plans. These documents constitute the AI tool’s validation package and are a prerequisite for deployment in a GMP environment.

 Table 7-2 List of Documents in the AI Tool Validation Package

Document Type	Items to Review	Common Omissions	Risk Level
User Requirements Specification (URS)	Prescribed Purpose and Performance Requirements	Vague description of intended use	High
Risk Assessment (RA)	Impact Assessment of Model Failure	Consequences of failure not assessed	High
Performance Qualification (PQ)	Performance Verification on Real Data	Validated only on demo data	High
Audit Trail	Recording of all operations	No audit trail functionality	High
Permissions Management	Access and Operation Permissions	No permission levels	Medium
Change Control	Management Process for Model Updates	No Change Notification Mechanism	High
Revalidation Plan	Plan for Periodic Revalidation	No revalidation plan	Medium

 Turn compliance from a slogan into verifiable documentation. If a supplier claims to be “GMP-validated” but cannot produce the aforementioned documents, that claim is unsubstantiated. The quality team should request that the supplier provide sample documents within one week of the meeting and specify the items to be verified. If the supplier fails to provide them, it should be excluded from the shortlist.

 7.3 BD and Management Should First Calculate Total Deployment Costs

 The total deployment cost of AI tools extends far beyond software licensing fees. When evaluating options, BD and management should calculate the following cost items: software licensing or subscription fees, data cleansing and standardization costs, integration costs with existing systems (MES, LIMS, ERP), validation costs (IQ/OQ/PQ), training costs, maintenance and upgrade costs, and vendor lock-in risk.

 Table 7-3 Breakdown of Total Deployment Costs for AI Tools

Cost Item	Estimated Percentage of Total Cost	One-time or Recurring	Notes
Software License Subscription	15 to 25%	Ongoing	Billed by number of users or batch volume
Data Cleaning and Standardization	20 to 30%	One-time	Often underestimated
System integration	15 to 25%	One-time	Integration with MES and LIMS
Validation (IQ, OQ, PQ)	10 to 20%	Single-use	GMP Environment Required
Training	5 to 10%	Ongoing	Initial and post-change
Maintenance and Upgrades	10 to 15%	Ongoing	Annual maintenance fee
Vendor Lock-in Risk	Difficult to quantify	Potential	Data migration costs

 The table above lists the seven components of the total deployment cost for AI tools. Any claim of cost reduction and efficiency improvement must be based on a baseline and quantifiable results. If a vendor claims to reduce production costs by 30%, you should ask what the baseline is, how the 30% figure was calculated, and whether there are comparable case studies. If the vendor cannot provide baseline data and a quantification method, its cost-reduction claim lacks substantiation.Business Development (BD) and management should request that the vendor provide a breakdown of total costs and the ROI calculation methodology, to be used as key documents during post-meeting evaluations.

 In addition to the evaluation priorities for the three roles mentioned above, meeting participants should also focus on the maturity of the AI vendor itself.One question worth asking is: How many members of the vendor’s AI team have work experience in a biopharmaceutical GMP environment? If the AI team’s background is primarily in the IT or internet industries, their understanding of GMP, validation, and change control may be insufficient, which could impact the compliant design of the product. Another question is whether the vendor has successful case studies from clients where the solution has been deployed. If the vendor can only provide laboratory demonstration results but lacks actual deployment experience in a GMP environment, the applicability of its solution in actual production is questionable.

 Attendees should also pay attention to the vendor’s business sustainability.The deployment cycle for AI tools typically takes 6 to 18 months, encompassing procurement, integration, validation, and training. If the supplier encounters financial difficulties or is acquired during this period, deployment may be disrupted. Business Development (BD) and management should evaluate the supplier’s financial health, ownership structure, and recent funding history as factors in the supplier selection process. Although this falls outside the scope of technical evaluation, for AI tools requiring long-term maintenance, the supplier’s business sustainability is just as important as its technical capabilities.

 Ongoing monitoring after deployment is an often-overlooked aspect of AI tool lifecycle management. Models may perform well during validation but may experience performance degradation in production environments due to data drift, process changes, or equipment aging.Pharmaceutical companies should establish a mechanism for continuous monitoring of model performance—regularly calculating the model’s prediction accuracy, false positive rate, and false negative rate on production data, and comparing these metrics to validation baselines. If performance metrics deviate from the baseline by more than a preset threshold, a model re-evaluation process should be triggered. This continuous monitoring mechanism should be incorporated into Standard Operating Procedures (SOPs) and validation documentation prior to model deployment, rather than added ad hoc after deployment.

 Pharmaceutical companies should also establish data-sharing mechanisms for performance monitoring with suppliers. If suppliers monitor model performance via remote access, pharmaceutical companies must clearly define the security boundaries for data transmission and privacy protection measures. Production data is a core asset of pharmaceutical companies; transmitting data to suppliers requires an information security assessment and contractual agreements. It is recommended to specify the scope of data use, retention periods, and destruction requirements in quality agreements.

 8. After the meeting, AI case studies should be categorized into three types rather than compiled into a collection of success stories

 When organizing AI case studies after the meeting, avoid compiling them into a collection of success stories. Instead, categorize the cases into three groups: the first category consists of cases that have been integrated into controlled processes and have yielded quantifiable benefits; the second category includes cases that have generated clinical or manufacturing validation signals; and the third category comprises cases that remain at the conceptual demonstration stage. For each case, document the data sources, intended use, validation status, action plan, and regulatory status.

 Table 8-1: Three-Tier Classification Criteria for AI Cases

Category	Characteristics	Evidence Requirements	Credibility	Purpose
Category 1: Has been incorporated into a controlled process	Incorporated into SOPs; provides quantifiable benefits and audit trail	Complete validation package plus change control plus quantifiable results	High	Can be directly referenced for deployment
Category 2: Generates validation signals	Includes external validation data and a designed action plan	External validation plus action plan	Medium	Can serve as a reference for pilot projects
Category 3: Concept Presentation	Demonstration data only; no external validation	None	Low	For technical tracking only

 8.1 Pre-publication Review of Original Sources for Conferences and AI Projects

 Conference dates, location, venue, and agenda are subject to the official websites of Biotech Week Boston and BPI, specifically informaconnect.com/biotech-week-boston/. Regulatory approvals and clinical program statuses are subject to regulatory filings, trial registrations, and original company announcements. Before publishing any conference-related articles or reports, verify the following information:

 Conference Information Verification: Confirm that the dates are September 22–25, 2026; the location is the Hynes Convention Center in Boston; and the flagship section is BioProcess International. This information is subject to the official website and not to third-party media reports.

 Verification of AI Project Status: If an article cites clinical progress for a specific AI drug or AI tool, verify the trial status via ClinicalTrials.gov, check the regulatory approval status on the FDA or EMA websites, and review the latest developments in the company’s annual reports or press releases. Do not cite unverified media reports or industry overviews.

 Verification of attendance figures—the 2026 figure of over 5,000 attendees is based on the official website, while the 2025 figure of over 4,000 is based on historical data. These two figures must not be used interchangeably; when citing them, the year and source must be clearly indicated.

 8.2 Prioritization and Action Tracking of Post-Conference Cases

 After verifying the sources of case information in Section 8.1, the next step is to determine priorities and allocate resources. Resource allocation should clearly differentiate among three categories of cases: Category 1 cases require immediate initiation of internal evaluation; Category 2 cases should be scheduled for periodic follow-up; and Category 3 cases should be archived for future reference.Prioritization is based on two factors: evidence maturity and alignment with business needs. Evidence maturity determines whether a case has the technical foundation for internal reuse; alignment with business needs determines whether the case addresses current technical or quality pain points the company is facing. Cases with high scores on both factors should be assigned P0 priority; those meeting only one factor should be assigned P1; and those where neither factor is clear should be assigned P2.

Case Categories	Priority	Action Type	Person in Charge	Timeline
Category 1 (Already in the controlled process)	P0 (Highest)	Internal evaluation and assessment of reusability feasibility	Technical Assessment Lead and Quality Audit Lead	Within 30 days after the meeting
Category II (Validation Signal Generated)	P1: Moderate	Track progress and provide regular updates	Individual attendees	Quarterly updates
Category 3 (Concept Demonstration)	P2 (Minimum)	Archived for reference	Team-shared maintenance	Annual Review

 The priority allocation defined in the table above is based on the following assessment: Category 1 cases have the highest maturity level, and missing the evaluation window may result in the loss of technical opportunities. In the BPI agenda, there are typically no more than 5 to 8 Category 1 cases, and it is feasible to complete their evaluation within 30 days.Category 2 cases typically number between 15 and 20; quarterly updates can cover the release cycles of most validation data. Category 3 cases can be archived and reviewed collectively during the annual technical planning review. It is important to note that priorities are not fixed—Category 2 cases should be upgraded to Category 1 evaluation if new Phase II or Phase III clinical data becomes available; Category 3 cases should be upgraded to Category 2 tracking if external validation results emerge in subsequent meetings.

Evaluation Dimensions	Specific Content	Acceptance Criteria	Non-Compliance Handling
Data Source	Source and Size of Training Data Batches	Data from GMP or engineering batches	Downgraded to Class II monitoring
CQA Link	Prediction Correlation with Product Quality Attributes	Evidence of CQA association	Downgraded to Class II follow-up
Validation Status	External Validation and Performance Metrics	Data requiring cross-center validation	Downgraded to Class II tracking
Action Path	SOP References and Change Logs	SOP reference records are available	Downgraded to Category II tracking
Change Control	Version Control and Change Control Documentation	Change Control Process in Place	Require supplier to provide additional information
Cost Assessment	Total Cost of Deployment and ROI Estimates	Baseline comparison data available	Postpone the deployment decision

 The internal evaluation of a case study involves not only a technical review but also an assessment of the feasibility of deployment within the company. The evaluation team needs to address questions on three levels: First, the technical level—can the model’s predictive performance be replicated using the company’s process data? This requires the supplier to provide test results of the model using similar process data from the company or to arrange a small-scale internal validation. Second, the quality level—does the model’s validation package meet the requirements of the company’s GMP system?This requires a line-by-line comparison against the validation document checklist listed in Chapter 7 to identify which documents the supplier needs to supplement. Third, the resource level—what are the costs associated with data cleaning, system integration, and training required to deploy the model? This requires a joint estimate by the IT and process teams, referencing the cost breakdown table in Chapter 7. Failure to meet standards in any of these three levels means the case is not yet ready to proceed to an internal pilot.

Case Categories	Exit Criteria	Upgrade Criteria	Trigger Action
Category 1	Failed Evaluation	None	Record the reason and file it
Category 1	Evaluation passed	None	Proceed to internal pilot preparation
Category II	No new validation data for 12 months	Phase II or Phase III data available	Downgraded to Class III and archived
Class II	None	SOP reference records appear	Upgraded to Class I evaluation
Class III	No progress in the annual review	None	Archived for future reference
Category 3	None	External validation data found	Escalate to Category 2 tracking

 The core of the tracking mechanism is to establish clear exit and escalation criteria to prevent the case repository from expanding indefinitely without resulting in action. Participants should submit a brief meeting summary to management within two weeks of the meeting, including a list of Category I, II, and III cases, corresponding action recommendations, and resource requirements. This summary should serve as an input for the company’s annual AI technology plan, rather than merely serving as personal post-meeting notes.Post-meeting action tracking should also be integrated with the company’s annual quality system review—if an assessment of a Category 1 case reveals gaps in the model validation package, it should trigger the supplier quality communication process, requiring the supplier to supplement the documentation within an agreed-upon timeframe. This approach of integrating post-meeting action tracking with the quality system ensures that the benefits gained from BPI participation extend beyond a mere technical activity to serve as a trigger for the company’s controlled management processes.This is precisely the core issue to be discussed in the conclusion of Chapter 9: Can AI tools support a verifiable decision?

 9. Conclusion: The dividing line for AI in the biopharmaceutical industry is whether it can make a verifiable decision

 Looking back at the discussion throughout this paper, the application of AI in the biopharmaceutical industry can be boiled down to a single dividing line: whether AI tools can make a verifiable decision.

 Internal evaluation of a given use case involves not only a technical review but also an assessment of the feasibility of deployment within the company. The evaluation team must address questions on three levels: First, the technical level—can the model’s predictive performance be replicated using the company’s own process data? This requires the supplier to provide test results of the model on similar process data from the company or to arrange a small-scale internal validation. Second, the quality level—does the model’s validation package meet the company’s GMP system requirements?This requires a line-by-line comparison against the validation document checklist listed in Chapter 7 to identify which documents the supplier needs to supplement. Third, the resource level—what are the costs associated with data cleaning, system integration, and training required to deploy the model? This requires a joint estimate by the IT and process teams, referencing the cost breakdown table in Chapter 7. Failure to meet standards at any of these three levels means the case is not yet ready to enter the internal pilot phase.

 The priority allocation defined in the table above is based on the following assessment: Category 1 cases have the highest maturity level, and missing the evaluation window may result in the loss of technical opportunities. The BPI agenda typically includes no more than 5 to 8 Category 1 cases, and it is feasible to complete their evaluation within 30 days.Category 2 cases typically number between 15 and 20; quarterly updates can cover the release cycles of most validation data. Category 3 cases can be archived and reviewed collectively during the annual technology planning review. It is important to note that priorities are not fixed—Category 2 cases should be upgraded to Category 1 evaluation if new Phase II or Phase III clinical data becomes available; Category 3 cases should be upgraded to Category 2 tracking if external validation results emerge in subsequent meetings.

 In drug discovery, this dividing line is reflected in whether AI-generated candidate molecules can be linked to verifiable biological hypotheses, and whether Phase II/III clinical results can quantify the AI’s contribution.In the clinical domain, the dividing line lies in whether AI tools can transition from investigational use to formal decision-making processes, and whether predictive results correspond to clear action pathways. In the manufacturing domain, the dividing line lies in whether models can link CPPs to CQAs and modify operations within defined boundaries. In the CMC and regulatory domains, the dividing line lies in whether the chain of evidence is closed and whether the intended use aligns with the strength of the evidence.

 A truly mature AI tool should possess the following five characteristics: First, a clear intended use—it can specify the specific decisions for which the model is used, with clearly defined boundaries of use; Second, reliable data—the sources of training and validation data are clearly identified, include abnormal operating conditions, and the data quality has been assessed; Third, interpretable outputs—the model can explain the key drivers of its predictive results and is not a “black box”;Fourth, a defined course of action—predictive results correspond to clear action plans, approval workflows, and audit trails; Fifth, validation and rollback mechanisms—including a comprehensive validation package, change control, and contingency plans for anomalies.

 Models that merely enhance narrative appeal but fail to integrate into controlled processes should not be regarded as productivity breakthroughs. This criterion applies to all AI case studies presented at BPI—no matter how advanced the technology may seem, if it cannot answer these five questions—“What decisions does it support?”, “Where does the data come from?”, “How are the results explained?”, “How are actions taken?”, and “How is a rollback performed?”—it remains at the conceptual stage.The value of Biotech Week Boston 2026 lies precisely in the fact that it provides the industry with a platform to scrutinize these questions. In the exhibition halls and on the agenda in Boston, every AI claim should be evaluated against the standard of “whether it can support a verifiable decision.”

 Returning to the agenda of Biotech Week Boston 2026 itself, this conference provides the industry with a centralized platform to scrutinize AI claims.In the BPI exhibition hall, vendors will showcase the latest versions of their AI tools; during agenda presentations, pharmaceutical companies and academic institutions will share preliminary results from AI applications; and in informal discussions, attendees will exchange honest assessments of AI’s actual effectiveness. The cross-validation of these three sources of information provides a more accurate picture of AI’s true status in the biopharmaceutical industry than any single source alone.

 The key action attendees should take after the conference is to return to their organizations and reassess internal AI projects using the “verifiable decision-making” standard; collecting business cards and PowerPoint presentations is merely a byproduct. Every project should answer five questions: What decisions does it support? Where does the data come from? How is it interpreted? How is action taken?What is the fallback plan? If any of these five questions cannot be answered, the project must be put on hold until the evidence is supplemented. This self-regulated approach to evaluation is far less costly than having to remedy gaps discovered during a regulatory audit.

 On a broader level, Biotech Week Boston 2026 will examine whether an industry consensus has emerged: that the value of AI in biopharmaceuticals lies not in the algorithms themselves, but in whether those algorithms can be integrated into controlled development and quality decision-making processes. If this consensus gains the endorsement of industry participants during the BPI agenda discussions, it will drive AI’s transition from a marketing concept to an engineering practice. Attendees should play an active role in shaping the specific details of this consensus through their own judgment and questions.

 Table 9-1: Evaluation Table of Five Characteristics of Mature AI Tools

Characteristic	Specific Meaning	Evaluation Questions	Qualification Criteria
Clear Purpose	Can clearly explain what decisions the model is used for	What specific decision-making process does the model support?	The description of the purpose is well-defined
Reliable Data	The sources of training and validation data are clearly identified	Where does the data come from, and how many batches are there?	Includes data from abnormal operating conditions
Interpretable output	The model can explain the key factors behind the prediction results	How to interpret the prediction results	Traceable predictors
Action paths	Action Plans Corresponding to Prediction Results	Actions to Take After the Prediction	Approval and audit records
Validation and Fallback	Includes a comprehensive validation package and fallback mechanism	How to roll back to a safe state	Change control process in place

 10. Biotech Week Boston 2026 Frequently Asked Questions

 10.1 When and Where Will Biotech Week Boston 2026 Take Place?

 Biotech Week Boston 2026 will take place from September 22 to 25, 2026, in Boston, USA. According to the BPI official website, the venue is the Hynes Convention Center. The week-long event includes co-located events such as BioProcess International; specific venue arrangements for each co-located event are subject to the final announcement on the official website.

 10.2 What Are the Key Topics to Be Discussed at BioProcess International 2026?

 According to information on the official website, the key agenda topics for BioProcess International 2026 include:

 Cell line development—focusing on expression system optimization, clone screening, and stability studies

 Upstream Process—Focusing on cell culture processes, feed strategies, and process control

 Downstream Purification—Focusing on chromatography, filtration, and recovery optimization

 Digital Biomanufacturing—Focusing on process analytics, digital twins, and automated control

 CMC Strategy—Focusing on Design for Quality, stability studies, and regulatory communication

 Cell and Gene Therapy — Focus on CGT process development, analysis, and supply chain

 CDMO Collaboration — Focus on outsourcing strategies and technology transfer

 Do not confuse the agendas of different co-events throughout the week—Biotech Week Boston includes multiple co-events, and BPI is just one of them. Other co-events may have different agenda priorities.

 10.3 How to Determine Whether an AI-in-Biomanufacturing Case Study Is Reliable

 The following seven criteria can be used to determine whether an AI-driven biomanufacturing case study is reliable:

 Authentic production data: Is the model validated using GMP production data, rather than presented solely based on development experimental data?

 Linkage to Critical Quality Attributes (CQAs): Are the model’s predictions directly correlated with CQAs (purity, aggregates, potency, etc.)?

 External validation: Has the model been validated using data from outside the training set?

 SOP Implementation: Have the model’s recommendations been incorporated into standard operating procedures (SOPs) with clear action plans?

 Version and Change Control: Does the model have version management, change control, and a revalidation plan?

 Audit trail—Are there complete audit records for all model-based decisions?

 Quantifiable Benefits: Does the model deliver quantifiable benefits (e.g., reduction in bias, shorter release times, improved batch pass rates)?

 10.4 How to Find the Boston Bio Conference

 To find this conference, readers should search using the official names “Biotech Week Boston” or “BioProcess International” and verify the information through the Informa Connect website. The official URL is informaconnect.com/biotech-week-boston/.

 When searching, using “Boston Bio 2026” or “Biotech Week Boston 2026” will more accurately pinpoint this conference. A search for “BPI 2026” will also lead to BioProcess International, the flagship section of the same conference.

 If you are unable to attend Biotech Week Boston 2026, you can access conference information through the following channels: After the event, Informa Connect typically publishes a conference recap and selected presentation videos; the BPI website updates with agenda summaries and speaker profiles; and industry media outlets publish conference coverage, though you should be sure to verify the sources of this information. It is recommended to rely primarily on official channels, supplement them with third-party reports, and verify the original sources before citing any information.

 Table 10-1 Biotech Week Boston 2026 Quick Reference Table

Question	Answer	Source
When is it held?	September 22–25, 2026	BPI Official Website
Where	Hynes Convention Center, Boston, USA	BPI Official Website
Flagship Section	BioProcess International	Conference Website
Official Website	informaconnect.com/biotech-week-boston/	Conference Website
Expected Attendance in 2026	Over 5,000	Conference Official Website (2026 Projections)
Actual attendance in 2025	Over 4,000	Historical figures

 Table 10-2: Seven-Point Reliability Checklist for AI-Driven Biomanufacturing Case Studies

Inspection Item	Inspection Content	Pass Criteria
Real Production Data	Model validated using GMP data	GMP batch validation results available
CQA integration	Predictions correlated with product quality attributes	Evidence of CQA association
External validation	Validation outside the training center	Cross-center validation data available
SOP Actions	Recommended for inclusion in Standard Operating Procedures	SOP reference records are available
Version Control	Version management and change control are in place	Change control documentation is in place
Audit Trail	Decisions are fully documented	Audit logs are maintained
Quantifiable benefits	Quantifiable benefit metrics	Baseline Comparison Data

 The seven criteria listed above can serve as a tool for participants to quickly assess the reliability of AI case studies during the BPI agenda. Each criterion corresponds to a specific verification dimension; the absence of any one of them raises doubts about the case study’s maturity and requires further verification after the meeting.